The Biosimilars Council is calling for inclusion of an affirmative statement to allow for a better understanding of treatment options and more affordable medicines.
The portfolio to be acquired consists of global NRT brand Nicotinell and local brands Nicabate, Habitrol and Thrive in markets outside of the United States.